Revive owns the patented Bucillamine and that is what counts from this point on. All being well, CEO Michael Frank will clo$e a deal which will provide shareholder value.
No-one gives a cockroach's ass cheek what you claim in your BS posts. Receive a very hard albeit virtual punch in the throat you soppy little Cant. Bucillamine has a chance whereas you project to always be a pathetic little turd basically...LOFL!
Right, I am off for an early lunch at The Bellagio. Cheers to Bucillamine's potential!
It will be an R/S. That will regenerate the cash flow to keep financing the salaries and bonuses. It is what it is. Unfortunately this was simply an EUA dream, just like so many other tiny biotech during the COVID era. I got a burned a bit by the the same dream with RLFTF. They did the nasty R/S (1 for 400), which wiped the SH out. Ouch. Of course they sold the R/S with PRs that it was to get to the NASDAQ, which never happened. It's SOP in the pennyworld.
News 
Market Data 
Discover 
AI
